- Home
- FBIO vs IGC Comparison
FBIO vs IGC Comparison
Compare FBIO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBIO | IGC |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 31.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FBIO | IGC |
|---|---|---|
| Price | $4.36 | $0.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $16.50 | $4.13 |
| AVG Volume (30 Days) | 719.4K | ★ 1.0M |
| Earning Date | 11-14-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,303,000.00 | $1,106,000.00 |
| Revenue This Year | $29.71 | $3.54 |
| Revenue Next Year | $49.34 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $0.25 |
| 52 Week High | $4.39 | $0.50 |
Technical Indicators
Market Signals| Indicator | FBIO | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 77.96 | 47.54 |
| Support Level | $4.02 | $0.28 |
| Resistance Level | $4.39 | $0.31 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 95.72 | 43.24 |
Price Performance
Historical ComparisonAbout FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.